Severe Hypercholesterolemia Caused by Mesalazine Which Is a Key Drug of Ulcerative Colitis: A Case Report

Drug-induced hypercholesterolemia is well known to cause side effects, such as secondary hypercholesterolemia. Many of these drugs are essential for long-term use and are difficult to replace; therefore, they are continued even when associated with hypercholesterolemia. Mesalazine is the first-line drug used for treating ulcerative colitis. We herein report a case of severe hypercholesterolemia following mesalazine administration in a patient with ulcerative colitis. In this case, a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor was effective in dramatically improving severe hypercholesterolemia. Clinicians should therefore be aware of the possibility of severe hypercholesterolemia caused by mesalazine for educational purposes.

Authors

Institutions

Publication Details

Journal
Internal Medicine
Published
2025-12-24
DOI
https://doi.org/10.2169/internalmedicine.6599-25
Citations
1
Primary Topic
Inflammatory Bowel Disease
Type
article
Field-Weighted Citation Impact
1.82
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Severe Hypercholesterolemia Caused by Mesalazine Which Is a Key Drug of Ulcerative Colitis: A Case Report

Kazutoshi Murakami, Kohei Kaku, Shinji Kamei, Takatoshi Anno et al.
1 citations
Internal Medicine
Inflammatory Bowel Disease
1.82
article

Severe Hypercholesterolemia Caused by Mesalazine Which Is a Key Drug of Ulcerative Colitis: A Case Report

Kazutoshi Murakami, Kohei Kaku, Shinji Kamei, Takatoshi Anno, Jun Wada, Hideaki Kaneto, Shuhei Nakanishi
article en
1 citations

Abstract

Drug-induced hypercholesterolemia is well known to cause side effects, such as secondary hypercholesterolemia. Many of these drugs are essential for long-term use and are difficult to replace; therefore, they are continued even when associated with hypercholesterolemia. Mesalazine is the first-line drug used for treating ulcerative colitis. We herein report a case of severe hypercholesterolemia following mesalazine administration in a patient with ulcerative colitis. In this case, a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor was effective in dramatically improving severe hypercholesterolemia. Clinicians should therefore be aware of the possibility of severe hypercholesterolemia caused by mesalazine for educational purposes.

Internal Medicine
Okayama University (JP), Kurashiki Central Hospital (JP), Kawasaki Medical School Hospital (JP)
Good health and well-being
Openalex Percentile: Top 10%
Inflammatory Bowel Disease
1.82
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Severe Hypercholesterolemia Caused by Mesalazine Which Is a Key Drug of Ulcerative Colitis: A Case Report — Kazutoshi Murakami, Kohei Kaku, et al. · Internal Medicine (2025) | TGRS Research Map | TGRS